Nicotinamide Riboside Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Nicotinamide Riboside evidence and protocol review

Longevity Research compound PowderCapsule needs_revision Best effort · source review pending

Also known as: NR, Niagen reference

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes
1 g, 5 g, 10 g
Storage
No approved consumer storage standard exists for this presentation; follow the lot-specific COA and validated stability data
Solubility
Freely water-soluble as NR chloride salt

Best-Effort Research Profile

Nicotinamide riboside (NR) is an NAD+ precursor vitamin B3 form, converted to NAD+ via the NRK1/NRK2-mediated salvage pathway (a distinct entry point from NMN). Multiple randomized controlled human trials confirm NR supplementation reliably raises blood NAD+ metabolome levels; functional/clinical endpoint benefits (metabolic, cognitive) are more variable and depend on population and dose, mirroring the broader NAD+ precursor literature.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life
Rapidly metabolized to NAD+ intracellularly; not meaningfully characterized as standalone plasma half-life
Onset
NAD+ level increases measurable within weeks in RCTs
Administration Routes (Research)
Oral

Reported Research Effects

Reported Research Side Effects

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Route-Specific Research Protocols

Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.

Label / guideline Human study Community only Preclinical only Not established
Oral Human study only

300-1000 mg/day in published human studies

Frequency / timing
Daily
Duration / setting
Study-specific
Technique
Oral
Evidence
Human study protocol

Context: human NAD-metabolism trials

Formulation: Oral-mucosal formulations are not dose-equivalent to injectable or topical formulations.

Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.

Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.

Research Notes

Nicotinamide riboside raises blood NAD-related metabolites, but clinical outcome benefits are not established across indications.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources Under Review

Nicotinamide riboside randomized human trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/29599478/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Articles

Published articles on this site that mention Nicotinamide Riboside or one of its catalog aliases.

Related Research Tools

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.

Scroll to Top